Mesembrine
Chemistry
- CID: 394162 · PubChem
- Formula: C17H23NO3
- Molecular weight: 289.4 g/mol
- IUPAC: (3aS,7aS)-3a-(3,4-dimethoxyphenyl)-1-methyl-2,3,4,5,7,7a-hexahydroindol-6-one
- CAS: 24880-43-1
Family & pharmacology
Family: Sceletium alkaloid (mesembrane-type tricyclic)
Pharmacological class: Serotonin reuptake inhibitor (SRI) and phosphodiesterase type 4 (PDE4) inhibitor. Mesembrine inhibits the serotonin transporter (SERT) with potency comparable to SSRIs, increasing synaptic serotonin availability. The concurrent PDE4 inhibition — which raises intracellular cAMP — is a mechanistic feature not found in conventional SSRIs and may contribute to anxiolytic and cognitive effects observed in preclinical and clinical studies. Mesembrine does not exhibit monoamine oxidase inhibition at relevant concentrations.
Natural source: Mesembrine is the primary alkaloid in Sceletium tortuosum (kanna), a small succulent plant native to the semi-arid regions of South Africa, particularly the Western Cape and Northern Cape provinces. The plant contains at least four major alkaloids (mesembrine, mesembrenone, mesembrenol, and mesembranol); mesembrine typically predominates in fermented preparations (called kougoed). Total alkaloid content varies significantly between chemotypes and growing conditions.
Historical context
Sceletium tortuosum has one of the longest documented histories of use of any psychoactive plant. The earliest written account was by Jan van Riebeeck, the Dutch VOC commander who established the Cape Colony, who recorded Khoisan use of kanna in his diary in 1662. Subsequent colonial-era accounts describe kanna as a valuable trade commodity between Khoisan groups, sometimes used in lieu of tobacco or exchanged for livestock.
Mesembrine as an alkaloid was first isolated in 1898 by German pharmacologists Bodendorf and Krieger from dried Sceletium material. Its full chemical structure was elucidated over the following decades, with the mesembrane carbon skeleton fully described by the mid-20th century. Modern pharmacological characterisation of its serotonergic mechanism was established in the 1990s.
Traditional use
- Khoisan and early Cape Coloured communities chewed, smoked, or used fermented kanna (kougoed) as snuff for mood elevation, sociality, and pain relief
- Hunters used kanna to suppress hunger and thirst on long treks; it was also used for toothache and intestinal complaints
- Kanna functioned as an important trade good between Khoisan groups across the Cape, sometimes commanding high barter value
- Fermentation (kougoed preparation) involved burying plant material and allowing it to ferment over days, which transforms alkaloid ratios — increasing mesembrenone relative to mesembrine and affecting potency
Modern research context
Scientific interest in mesembrine and Sceletium extracts accelerated from the 2000s. The commercial extract Zembrin® (a standardised 2:1 extract of Sceletium tortuosum) has been evaluated in multiple clinical studies. Harvey et al. published the first randomised controlled trial in humans in 2011 (J Ethnopharmacol 2011, PMID 22234675), demonstrating anxiolytic effects and improved cognitive flexibility in healthy volunteers.
A subsequent randomised double-blind crossover trial (Nell et al. 2013) found that Zembrin attenuated threat-related amygdala reactivity in healthy subjects — a finding consistent with anxiolytic activity. The dual SRI+PDE4 mechanism distinguishes mesembrine from classic SSRIs, and its relatively rapid onset of effect (hours rather than weeks, as reported in qualitative user accounts) has been a subject of mechanistic interest. PDE4 inhibition alone (as seen in roflumilast) has antidepressant-like effects in animal models, potentially synergising with SERT blockade.
Safety
Mesembrine and Sceletium tortuosum preparations are generally considered to have a benign safety profile at low-to-moderate doses. Reported adverse effects include mild headache, nausea, and initial sedation. The most significant pharmacological interaction risk is with other serotonergic agents: co-administration of Sceletium preparations with SSRIs, SNRIs, or MAOIs raises the theoretical risk of serotonin syndrome and should be avoided. Case reports of serotonin syndrome with kanna have appeared in the literature.
Sceletium has no meaningful cardiovascular or hepatotoxic risk profile at doses used traditionally or in clinical studies. It is not considered habit-forming in the classical sense, though tolerance and mild psychological dependence are plausible with regular high-dose use. It is not recommended during pregnancy or lactation in the absence of safety data.
Legal status in Germany
As of 2026, mesembrine and Sceletium tortuosum are not scheduled in the German Narcotics Act (BtMG, Anlagen I–III) or the New Psychoactive Substances Act (NpSG). The plant, its extracts, and mesembrine as an isolated alkaloid are legal to possess, sell, and purchase in Germany. Kanna and Sceletium extracts are openly available in health supplement and botanical retail channels in Germany and the EU.